Fulgent Genetics, Inc. FLGT Therapeutic Development — Finite Lived Intangible Assets Accumulated Amortization
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets accumulated amortization?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — finite lived intangible assets accumulated amortization of $96K in Q1 2026.
- What does therapeutic development — finite lived intangible assets accumulated amortization mean?
- Measures the cumulative expense recognized to allocate the cost of finite-lived intangible assets over their estimated useful lives within the therapeutic development segment. A rising balance indicates the aging of the segment's current intellectual property portfolio.